%0 Journal Article
%T The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022.
%A MacCallum-Bridges C
%A Hirschtick JL
%A Patel A
%A Orellana RC
%A Elliott MR
%A Fleischer NL
%J Ann Epidemiol
%V 92
%N 0
%D 2024 Apr 19
%M 38382771
%F 6.996
%R 10.1016/j.annepidem.2024.02.007
%X <B>OBJECTIVE: </B>To estimate the association between COVID-19 vaccination status at the time of COVID-19 onset and long COVID prevalence.<BR><B>METHODS: </B>We used data from the Michigan COVID-19 Recovery Surveillance Study, a population-based probability sample of adults with COVID-19 (n = 4695). We considered 30-day and 90-day long COVID (illness duration ≥30 or ≥90 days, respectively), using Poisson regression to estimate prevalence ratios (PRs) comparing vaccinated (completed an initial series ≥14 days before COVID-19 onset) to unvaccinated individuals (received 0 doses before COVID-19 onset), accounting for differences in age, sex, race and ethnicity, education, employment, health insurance, and rurality/urbanicity. The full unvaccinated comparison group was further divided into historic and concurrent comparison groups based on timing of COVID-19 onset relative to vaccine availability. We used inverse probability of treatment weights to account for sociodemographic differences between groups.<BR><B>RESULTS: </B>Compared to the full unvaccinated comparison group, the adjusted prevalence of 30-day and 90-day long COVID were lower among vaccinated individuals [PR30-day= 0.57(95%CI:0.49,0.66); PR90-day= 0.42(95%CI:0.34,0.53)]. Estimates were consistent across comparison groups (full, historic, and concurrent).<BR><B>CONCLUSIONS: </B>Long COVID prevalence was 40-60% lower among adults vaccinated (vs. unvaccinated) prior to their COVID-19 onset. COVID-19 vaccination may be an important tool to reduce the burden of long COVID.